Navigation Links
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
Date:11/5/2007

e company's Web site is http://www.scheringplough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE:

The information in this press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to potential of INTEGRILIN(R) and further actions under the clinical trials. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from the forward-looking statements of Schering-Plough, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see the Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the third quarter 2007 10-Q of Schering-Plough.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)....J., Nov. 21 Ikaria Holdings, Inc....mpany of the Year by the New Jersey Technology Cou...n that provides business support, networking oppor...companies and their leaders. Ikaria earned the awa...nd unique product/service provision. , , "W...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Fi...nounced that the United States Food and Drug Admin...ROMACTA(R) (eltrombopag) for the treatment of thro...pathic) thrombocytopenic purpura (ITP) who have ha...unoglobulins or splenectomy. The approval is a sig...
(Date:11/20/2008)..., Calif., Nov. 20 Bionov...ill present results from the Phase 1B,clinical tr...static breast,cancer, BZL101, at the Society for ...ence in Atlanta, Georgia. The Company,s oral pres...nd will be presented as a part of the Best of the,...
(Date:11/20/2008)...v. 20 PAREXEL Internatio...l biopharmaceutical services provider, today annou... provide regulatory consulting and clinical resear...ice, PAREXEL now has locations throughout five imp... which also include Argentina, Brazil, Chile, and ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 1KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 2KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 3KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 5LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 1LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 2DNA sensors found to be an effective artificial nose 2696 1Stroke Undertreated 9939 1Stroke Undertreated 9939 2Stroke Undertreated 9939 3
...od and Drug,Administration (FDA) today issued the ...nitiatives/criticalpath/reports/generic.html">Crit... identifying many,of the unanswered scientific que...ions of commonly used drugs. , The report is part ...2004 to discern what challenges exist in moving a,...
...eNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge...that the United States Food and Drug Administratio...(IND) application for the,clinical development of ...he treatment of post-operative pain. Earlier this ... of M6G in Europe in,over 500 patients with post-o...
Other Medicine Technology:New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development 2FDA approves IND on Lead Product M6G 2
(Date:11/21/2008)...als showed Banzel proved effective against Lennox-...althDay News) -- A new drug called Banzel (rufinam...t for a severe form of epilepsy called Lennox-Gast...n announced Friday. , The approval was based on...ded patients ages 4 to 30. Compared to patients wh...
(Date:11/21/2008)...LADELPHIA, Nov. 21 NursingCenter.c...g education and peer reviewed content, has been,u...ts 350,000 registered,users. Powered by Lippincot...now,provides over 900 peer-reviewed continuing ed...cles from more than 50 leading nursing journals.,...
(Date:11/21/2008)...NKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ ...for medical intervention in treating 88 percent of...rcent of Americans treated for a chronic condition...pending and 75 percent of all medical costs. A pr...years by Medco Health Solutions, Inc. (NYSE: MHS...
(Date:11/21/2008)...n 430 B.C., a new and deadly diseaseits cause rema...ity-state was teeming with citizens, soldiers and ... Sparta. As streets filled with corpses, social or...ness returned twice and Athens lost a third of its...hens marked the beginning of the end of the Golden...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...confirmed a link between exercising and the preven...a study conducted researchers gathered results fro...0 to 69. Participants were asked about the level o...ent and adult years.Results show women who exercis...
...hat a few alcoholic beverages a month may reduce t...n // with high blood pressure. Researchers found w...ificantly lower risk of death by nearly 30 percent... also a reduced risk of cardiovascular disease dea...
... survival rate of breast cancer patients by 63 per...rd regimes available . The clinical trial strength...mestane, as a first option.// A study showed that ... chance of developing another tumor by 32 percent ...
...lition of Health for Asthmatics in Sports and Exer...ave an exercise test // to 127, 6- to 18-year ol...sk factors were determined by a 10-item questionna...n was a family member having allergies or asthma. ...
Other Medicine News:
...cal IOL is a foldable silicone IOL. It features a ...e inserted with The UNFOLDER® Silver-T Implant... first and only FDA-approved multifocal IOL, and t...nal visionnear, intermediate, and far. The ARRAY&r...
...ferred viscoelastic for phacoemulsification proced...rks from the start to the finish of the case. The ...lastic is the reason. The low to moderate vacuum f...nly a fraction of the viscoelastic agent. However,...
...scoelastic agent for the surgeon who performs cata... Amvisc possesses sufficient viscosity for excelle... is highly cohesive so that complete removal at th...ed. Amvisc is priced to compete with any sodium hy...
...onate (1.8%) viscoelastic solution combines maximu...flo maintains a deep anterior chamber and protects... ideal for routine cataract surgery but can be use...lastic. Combine all these properties with the conv...
Medicine Products: